BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 21598008)

  • 1. Oral administration of coenzyme Q₁₀ reduces MPTP-induced loss of dopaminergic nerve terminals in the striatum in mice.
    Kobayashi S; Muroyama A; Matsushima H; Yoshimura I; Mitsumoto Y
    Neurol Sci; 2012 Feb; 33(1):195-9. PubMed ID: 21598008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of striatal dopaminergic terminals during the early stage in response to MPTP injection in C57BL/6 mice.
    Muroyama A; Kobayashi S; Mitsumoto Y
    Neurosci Res; 2011 Apr; 69(4):352-5. PubMed ID: 21185886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The 5α-reductase inhibitor Dutasteride but not Finasteride protects dopamine neurons in the MPTP mouse model of Parkinson's disease.
    Litim N; Bourque M; Al Sweidi S; Morissette M; Di Paolo T
    Neuropharmacology; 2015 Oct; 97():86-94. PubMed ID: 26006269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemically administered neuregulin-1β1 rescues nigral dopaminergic neurons via the ErbB4 receptor tyrosine kinase in MPTP mouse models of Parkinson's disease.
    Depboylu C; Rösler TW; de Andrade A; Oertel WH; Höglinger GU
    J Neurochem; 2015 May; 133(4):590-7. PubMed ID: 25581060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanomicellar formulation of coenzyme Q10 (Ubisol-Q10) effectively blocks ongoing neurodegeneration in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model: potential use as an adjuvant treatment in Parkinson's disease.
    Sikorska M; Lanthier P; Miller H; Beyers M; Sodja C; Zurakowski B; Gangaraju S; Pandey S; Sandhu JK
    Neurobiol Aging; 2014 Oct; 35(10):2329-46. PubMed ID: 24775711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroprotection by Paeoniflorin in the MPTP mouse model of Parkinson's disease.
    Zheng M; Liu C; Fan Y; Yan P; Shi D; Zhang Y
    Neuropharmacology; 2017 Apr; 116():412-420. PubMed ID: 28093210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGb761 protects against nigrostriatal dopaminergic neurotoxicity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice: role of oxidative stress.
    Rojas P; Serrano-García N; Mares-Sámano JJ; Medina-Campos ON; Pedraza-Chaverri J; Ogren SO
    Eur J Neurosci; 2008 Jul; 28(1):41-50. PubMed ID: 18662333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroprotective effects of (+/-)-catechin against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity in mice.
    Ruan H; Yang Y; Zhu X; Wang X; Chen R
    Neurosci Lett; 2009 Jan; 450(2):152-7. PubMed ID: 19070648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Harpagoside attenuates MPTP/MPP⁺ induced dopaminergic neurodegeneration and movement disorder via elevating glial cell line-derived neurotrophic factor.
    Sun X; Xiong Z; Zhang Y; Meng Y; Xu G; Xia Z; Li J; Zhang R; Ke Z; Xia Z; Hu Y
    J Neurochem; 2012 Mar; 120(6):1072-83. PubMed ID: 22192054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble Epoxide Hydrolase Inhibition Attenuates MPTP-Induced Neurotoxicity in the Nigrostriatal Dopaminergic System: Involvement of α-Synuclein Aggregation and ER Stress.
    Huang HJ; Wang YT; Lin HC; Lee YH; Lin AM
    Mol Neurobiol; 2018 Jan; 55(1):138-144. PubMed ID: 28822080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuronal or inducible nitric oxide synthase (NOS) expression level is not involved in the different susceptibility to nigro-striatal dopaminergic neurotoxicity induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) between C57BL/6 and BALB/c mice.
    Ito T; Uchida K; Nakayama H
    Exp Toxicol Pathol; 2013 Jan; 65(1-2):121-5. PubMed ID: 21788124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroprotection by freshwater clam extract against the neurotoxin MPTP in C57BL/6 mice.
    Hsieh CC; Lin MS; Hua KF; Chen WJ; Lin CC
    Neurosci Lett; 2017 Mar; 642():51-58. PubMed ID: 28126590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-inflammatory and neuroprotective effects of an orally active apocynin derivative in pre-clinical models of Parkinson's disease.
    Ghosh A; Kanthasamy A; Joseph J; Anantharam V; Srivastava P; Dranka BP; Kalyanaraman B; Kanthasamy AG
    J Neuroinflammation; 2012 Oct; 9():241. PubMed ID: 23092448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel iron (II) preferring dopamine agonist chelator D-607 significantly suppresses α-syn- and MPTP-induced toxicities in vivo.
    Das B; Rajagopalan S; Joshi GS; Xu L; Luo D; Andersen JK; Todi SV; Dutta AK
    Neuropharmacology; 2017 Sep; 123():88-99. PubMed ID: 28533164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroprotective effects of madecassoside in early stage of Parkinson's disease induced by MPTP in rats.
    Xu CL; Qu R; Zhang J; Li LF; Ma SP
    Fitoterapia; 2013 Oct; 90():112-8. PubMed ID: 23876367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different susceptibility to 1-methyl-4-phenylpyridium (MPP(+))-induced nigro-striatal dopaminergic cell loss between C57BL/6 and BALB/c mice is not related to the difference of monoamine oxidase-B (MAO-B).
    Ito T; Suzuki K; Uchida K; Nakayama H
    Exp Toxicol Pathol; 2013 Jan; 65(1-2):153-8. PubMed ID: 21855308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyperi Rhizoma inhibits the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced reduction in nigrostriatal dopaminergenic neurons in estrogen-deprived mice.
    Kim HG; Hong J; Huh Y; Park C; Hwang DS; Choi JH; Oh MS
    J Ethnopharmacol; 2013 Jun; 148(1):322-8. PubMed ID: 23639362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroprotection in Parkinson models varies with toxin administration protocol.
    Anderson DW; Bradbury KA; Schneider JS
    Eur J Neurosci; 2006 Dec; 24(11):3174-82. PubMed ID: 17156378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coenzyme Q10 and nicotinamide and a free radical spin trap protect against MPTP neurotoxicity.
    Schulz JB; Henshaw DR; Matthews RT; Beal MF
    Exp Neurol; 1995 Apr; 132(2):279-83. PubMed ID: 7789466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
    L'Episcopo F; Tirolo C; Caniglia S; Testa N; Serra PA; Impagnatiello F; Morale MC; Marchetti B
    J Neuroinflammation; 2010 Nov; 7():83. PubMed ID: 21092260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.